TenNor Initiated Phase II Clinical Trial for Cirrhosis Hyperammonemia and Hepatic Encephalopathy

August 14, 2020. The phase II site initiation meeting of TNP-2092 capsule for the treatment of cirrhosis hyperammonemia and hepatic encephalopathy was held at the first affiliated hospital of Jilin University. This is a multiple ascending dose study for safety, pharmacokinetic and preliminary efficacy in cirrhosis hyperammonemia patients. Professor Junqi Niu, Vice President, Professor Yanhua Ding, Director of the Clinical Center and research team from the hospital, TenNor Therapeutics and CROs attended the meeting.

For more information, please go to：www.tennorx.com